Top-News
Professionelle Dienstleistungen Kanada

Fusion Pharmaceuticals Inc News

Aktie
WKN:  A2P7ZZ ISIN:  CA36118A1003 US-Symbol:  FUSN
21,50 $
-0,03 $
-0,14%
18:32:01 Uhr
Handeln Depot/Watchlist
Aktienanzahl *
72,41 Mio.
Marktkapitalisierung *
1,44 Mrd. €
Streubesitz
-
Index-Zugehörigkeit
-
IR-Website
zur Website
*Stand: 19.03.2024

Fusion Pharmaceuticals Inc News

19.03.24 - wallstreet:online Zentralredaktion
Neue Ära der Krebsbehandlung: Fusion Pharma von AstraZeneca für 2,4 Milliarden US-Dollar übernommen
Der britische Pharmakonzern Astra schnappt sich das kleine Biotech-​Unternehmen Fusion, um sich dessen Krebsbehandlung der nächsten Generation zu sichern. Was steckt ...
19.03.24 - Der Aktionär
Astrazeneca mit Doppelschlag: Nächste heiße Übernahme
07.07.21 - PR Newswire
Fusion Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Fusion Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
07.06.21 - PR Newswire
Fusion Pharmaceuticals Appoints Isabelle Dussault, Ph.D. as Senior Vice President, Research
Fusion Pharmaceuticals Appoints Isabelle Dussault, Ph.D. as Senior Vice President, Research PR Newswire
27.05.21 - PR Newswire
Fusion Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference
Fusion Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference PR Newswire
06.05.21 - PR Newswire
Fusion Pharmaceuticals Announces Clinical Collaboration with Merck to Evaluate Fusion's Targeted Alpha Therapy (TAT) in Combination with Merck's KEYTRUDA® (pembrolizumab) in Patients With Solid Tumors Expressing IGF-1R
Fusion Pharmaceuticals Announces Clinical Collaboration with Merck to Evaluate Fusion's Targeted Alpha Therapy (TAT) in Combination with Merck's KEYTRUDA® ...
14.04.21 - PR Newswire
Fusion Pharmaceuticals to Present at the Bloom Burton & Co. Healthcare Investor Conference
Fusion Pharmaceuticals to Present at the Bloom Burton & Co. Healthcare Investor Conference PR Newswire
01.04.21 - PR Newswire
Fusion Pharmaceuticals Announces Closing of Acquisition of IPN-1087, a Small Molecule Targeting NTSR1, from Ipsen
Fusion Pharmaceuticals Announces Closing of Acquisition of IPN-1087, a Small Molecule Targeting NTSR1, from Ipsen PR Newswire
01.04.21 - PR Newswire
Fusion Pharmaceuticals Appoints Donald Bergstrom, M.D., Ph.D., to Board of Directors
Fusion Pharmaceuticals Appoints Donald Bergstrom, M.D., Ph.D., to Board of Directors PR Newswire
25.03.21 - PR Newswire
Fusion Pharmaceuticals Announces Fourth Quarter 2020 Financial Results and Business Update
Fusion Pharmaceuticals Announces Fourth Quarter 2020 Financial Results and Business Update PR Newswire
02.03.21 - PR Newswire
Fusion Pharmaceuticals to Expand Pipeline with Acquisition of IPN-1087, a Small Molecule Targeting NTSR1, from Ipsen
Fusion Pharmaceuticals to Expand Pipeline with Acquisition of IPN-1087, a Small Molecule Targeting NTSR1, from Ipsen PR Newswire
23.02.21 - PR Newswire
Fusion Pharmaceuticals To Present At The Cowen 41st Annual Health Care Conference
Fusion Pharmaceuticals To Present At The Cowen 41st Annual Health Care Conference PR Newswire
05.01.21 - PR Newswire
2020 Canadian IPO mixed results - number (77) down, amount ($5.55B) up driven by PE-backed IPOs
2020 Canadian IPO mixed results - number (77) down, amount ($5.55B) up driven by PE-backed IPOs Canada NewsWire
10.12.20 - PR Newswire
Fusion Pharmaceuticals Initiates Multi-Dose Portion of Phase 1 Trial of FPI-1434 in Patients with Advanced Solid Tumors
Fusion Pharmaceuticals Initiates Multi-​Dose Portion of Phase 1 Trial of FPI-1434 in Patients with Advanced Solid Tumors PR Newswire
12.11.20 - PR Newswire
Fusion Pharmaceuticals to Present at the Jefferies Virtual London Healthcare Conference
Fusion Pharmaceuticals to Present at the Jefferies Virtual London Healthcare Conference PR Newswire
10.11.20 - PR Newswire
Fusion Pharmaceuticals Announces Third Quarter 2020 Financial Results and Business Update
Fusion Pharmaceuticals Announces Third Quarter 2020 Financial Results and Business Update PR Newswire
02.11.20 - PR Newswire
Fusion Pharmaceuticals Appoints Barbara Duncan as Chairperson of the Board of Directors
Fusion Pharmaceuticals Appoints Barbara Duncan as Chairperson of the Board of Directors PR Newswire
02.11.20 - PR Newswire
Fusion Pharmaceuticals Announces Collaboration with AstraZeneca to Develop and Commercialize Next-Generation Radiopharmaceuticals and Combination Therapies
Fusion Pharmaceuticals Announces Collaboration with AstraZeneca to Develop and Commercialize Next-​Generation Radiopharmaceuticals and Combination Therapies PR Newswire
29.09.20 - PR Newswire
Fusion Pharmaceuticals Appoints Maria Stahl as Chief Legal Officer
Fusion Pharmaceuticals Appoints Maria Stahl as Chief Legal Officer PR Newswire
10.09.20 - PR Newswire
Fusion Pharmaceuticals to Present at the Morgan Stanley Virtual 18th Annual Global Healthcare Conference
Fusion Pharmaceuticals to Present at the Morgan Stanley Virtual 18th Annual Global Healthcare Conference PR Newswire

Newssuche

Videos

29.05.24 +17,26%
Technical Trading: DAX Long Chance kurzfristig
DAX Long Typ: Turbo Open End WKN: VD5FWS Hebel: 28 Laufzeit: OpenEnd Einstieg: Market ... Mehr »